Letters to Policy Makers

Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.
2025 Federal Advocacy Letters
Barriers to Access
Physician Payment
CMS: Medicare – ACR comments on final 2025 Medicare Physician Fee Schedule – 1/17/2025
Access to Treatments
Medical Workforce
Coming soon
Telehealth
Coming soon
Research Funding
ACR Responds to FDA Laboratory Developed Tests Proposed Rule – 12/4/2023
ACR Joins Broad Coalition Letter in Support of CMS Implementing G2211 – 9/7/2023
ACR Leads Cognitive Specialties Coalition Letter in Support of CMS Implementing G2211 – 9/6/2023
ACR Joins Safe Step Coalition in Thanking House Leaders of the Safe Step Act – 7/11/2023
ACR Letter Addressing the High Prices of Drugs Covered under Medicare Part B – 5/5/2023
ACR Comments on IRA Drug Price Negotiation Guidance – 4/14/2023